Table 2.
Antibody titers after mRNA-1273 vaccination in peritoneal dialysis patients with immunosuppressive therapy.
| Patient | IS | Dosage | Indication | Antibody titer (U/mL) | Antibody titer (U/mL) |
|---|---|---|---|---|---|
| (Sex, age) | 4 weeks after 1st dose | 4 weeks after 2nd dose | |||
| M, 43 | CNI | 2mg q.d. | Lung transplant | <0.40 | <0.40 |
| Prednisolon | 5mg q.d. | ||||
| MMF | 250mg t.i.d. | ||||
| M, 43 | MMF | 500mg q.d. | Kidney graft failure | <0.40 | 234.00 |
| F, 35 | MMF | 500mg b.i.d. | Kidney graft failure | 27.10 | 250.00 |
| F, 74 | CNI Prednisolon |
0.5mg q.d. 2.5mg q.d. |
Kidney graft failure | 17.70 | 1330.00 |
| M, 54 | Prednisolon | 2.5mg q.d. | Kidney graft failure | 13.90 | 1543.00 |
| F, 55 | Prednisolon | 2.5mg q.d. | Kidney graft failure | 3.58 | 2500.00 |
| M, 76 | Ustekinumab | 90mg every 3 months | Psoriasis | 20.00 | 677.00 |
M, male; F, female; IS, immunosuppressive therapy; CNI, calcineurin inhibitor; MMF, mycophenolate-mofetil; Ustekinumab (anti-IL-12/23); < 0,4 U/mL = negative (lower limit); 2500 U/mL = maximum (upper limit).